STAT3 and cancer: Small‐molecule inhibitors or antagonistic antibodies targeting critical effectors of IL6 signaling including IL6 itself, IL6R, gp130, JAK1/JAK2 and STAT3 have recently been approved or are currently evaluated in several clinical trials with patients suffering from cancer entities with a documented involvement of HH/GLI signaling such as breast and non‐small‐cell lung cancer (for review, see Refs.